UK pharma major GSK yesterday announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...

The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...

GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...